Cargando…
Pharmacological characterization of mutant huntingtin aggregate-directed PET imaging tracer candidates
Huntington’s disease (HD) is caused by a CAG trinucleotide repeat expansion in the first exon of the huntingtin (HTT) gene coding for the huntingtin (HTT) protein. The misfolding and consequential aggregation of CAG-expanded mutant HTT (mHTT) underpin HD pathology. Our interest in the life cycle of...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8429736/ https://www.ncbi.nlm.nih.gov/pubmed/34504195 http://dx.doi.org/10.1038/s41598-021-97334-z |
_version_ | 1783750592796033024 |
---|---|
author | Herrmann, Frank Hessmann, Manuela Schaertl, Sabine Berg-Rosseburg, Karola Brown, Christopher J Bursow, Galina Chiki, Anass Ebneth, Andreas Gehrmann, Miriam Hoeschen, Nicole Hotze, Madlen Jahn, Stefanie Johnson, Peter D Khetarpal, Vinod Kiselyov, Alex Kottig, Karsten Ladewig, Stefanie Lashuel, Hilal Letschert, Sven Mills, Matthew R Petersen, Kathrin Prime, Michael E Scheich, Christoph Schmiedel, Gerhard Wityak, John Liu, Longbin Dominguez, Celia Muñoz-Sanjuán, Ignacio Bard, Jonathan A |
author_facet | Herrmann, Frank Hessmann, Manuela Schaertl, Sabine Berg-Rosseburg, Karola Brown, Christopher J Bursow, Galina Chiki, Anass Ebneth, Andreas Gehrmann, Miriam Hoeschen, Nicole Hotze, Madlen Jahn, Stefanie Johnson, Peter D Khetarpal, Vinod Kiselyov, Alex Kottig, Karsten Ladewig, Stefanie Lashuel, Hilal Letschert, Sven Mills, Matthew R Petersen, Kathrin Prime, Michael E Scheich, Christoph Schmiedel, Gerhard Wityak, John Liu, Longbin Dominguez, Celia Muñoz-Sanjuán, Ignacio Bard, Jonathan A |
author_sort | Herrmann, Frank |
collection | PubMed |
description | Huntington’s disease (HD) is caused by a CAG trinucleotide repeat expansion in the first exon of the huntingtin (HTT) gene coding for the huntingtin (HTT) protein. The misfolding and consequential aggregation of CAG-expanded mutant HTT (mHTT) underpin HD pathology. Our interest in the life cycle of HTT led us to consider the development of high-affinity small-molecule binders of HTT oligomerized/amyloid-containing species that could serve as either cellular and in vivo imaging tools or potential therapeutic agents. We recently reported the development of PET tracers CHDI-180 and CHDI-626 as suitable for imaging mHTT aggregates, and here we present an in-depth pharmacological investigation of their binding characteristics. We have implemented an array of in vitro and ex vivo radiometric binding assays using recombinant HTT, brain homogenate-derived HTT aggregates, and brain sections from mouse HD models and humans post-mortem to investigate binding affinities and selectivity against other pathological proteins from indications such as Alzheimer’s disease and spinocerebellar ataxia 1. Radioligand binding assays and autoradiography studies using brain homogenates and tissue sections from HD mouse models showed that CHDI-180 and CHDI-626 specifically bind mHTT aggregates that accumulate with age and disease progression. Finally, we characterized CHDI-180 and CHDI-626 regarding their off-target selectivity and binding affinity to beta amyloid plaques in brain sections and homogenates from Alzheimer’s disease patients. |
format | Online Article Text |
id | pubmed-8429736 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-84297362021-09-13 Pharmacological characterization of mutant huntingtin aggregate-directed PET imaging tracer candidates Herrmann, Frank Hessmann, Manuela Schaertl, Sabine Berg-Rosseburg, Karola Brown, Christopher J Bursow, Galina Chiki, Anass Ebneth, Andreas Gehrmann, Miriam Hoeschen, Nicole Hotze, Madlen Jahn, Stefanie Johnson, Peter D Khetarpal, Vinod Kiselyov, Alex Kottig, Karsten Ladewig, Stefanie Lashuel, Hilal Letschert, Sven Mills, Matthew R Petersen, Kathrin Prime, Michael E Scheich, Christoph Schmiedel, Gerhard Wityak, John Liu, Longbin Dominguez, Celia Muñoz-Sanjuán, Ignacio Bard, Jonathan A Sci Rep Article Huntington’s disease (HD) is caused by a CAG trinucleotide repeat expansion in the first exon of the huntingtin (HTT) gene coding for the huntingtin (HTT) protein. The misfolding and consequential aggregation of CAG-expanded mutant HTT (mHTT) underpin HD pathology. Our interest in the life cycle of HTT led us to consider the development of high-affinity small-molecule binders of HTT oligomerized/amyloid-containing species that could serve as either cellular and in vivo imaging tools or potential therapeutic agents. We recently reported the development of PET tracers CHDI-180 and CHDI-626 as suitable for imaging mHTT aggregates, and here we present an in-depth pharmacological investigation of their binding characteristics. We have implemented an array of in vitro and ex vivo radiometric binding assays using recombinant HTT, brain homogenate-derived HTT aggregates, and brain sections from mouse HD models and humans post-mortem to investigate binding affinities and selectivity against other pathological proteins from indications such as Alzheimer’s disease and spinocerebellar ataxia 1. Radioligand binding assays and autoradiography studies using brain homogenates and tissue sections from HD mouse models showed that CHDI-180 and CHDI-626 specifically bind mHTT aggregates that accumulate with age and disease progression. Finally, we characterized CHDI-180 and CHDI-626 regarding their off-target selectivity and binding affinity to beta amyloid plaques in brain sections and homogenates from Alzheimer’s disease patients. Nature Publishing Group UK 2021-09-09 /pmc/articles/PMC8429736/ /pubmed/34504195 http://dx.doi.org/10.1038/s41598-021-97334-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Herrmann, Frank Hessmann, Manuela Schaertl, Sabine Berg-Rosseburg, Karola Brown, Christopher J Bursow, Galina Chiki, Anass Ebneth, Andreas Gehrmann, Miriam Hoeschen, Nicole Hotze, Madlen Jahn, Stefanie Johnson, Peter D Khetarpal, Vinod Kiselyov, Alex Kottig, Karsten Ladewig, Stefanie Lashuel, Hilal Letschert, Sven Mills, Matthew R Petersen, Kathrin Prime, Michael E Scheich, Christoph Schmiedel, Gerhard Wityak, John Liu, Longbin Dominguez, Celia Muñoz-Sanjuán, Ignacio Bard, Jonathan A Pharmacological characterization of mutant huntingtin aggregate-directed PET imaging tracer candidates |
title | Pharmacological characterization of mutant huntingtin aggregate-directed PET imaging tracer candidates |
title_full | Pharmacological characterization of mutant huntingtin aggregate-directed PET imaging tracer candidates |
title_fullStr | Pharmacological characterization of mutant huntingtin aggregate-directed PET imaging tracer candidates |
title_full_unstemmed | Pharmacological characterization of mutant huntingtin aggregate-directed PET imaging tracer candidates |
title_short | Pharmacological characterization of mutant huntingtin aggregate-directed PET imaging tracer candidates |
title_sort | pharmacological characterization of mutant huntingtin aggregate-directed pet imaging tracer candidates |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8429736/ https://www.ncbi.nlm.nih.gov/pubmed/34504195 http://dx.doi.org/10.1038/s41598-021-97334-z |
work_keys_str_mv | AT herrmannfrank pharmacologicalcharacterizationofmutanthuntingtinaggregatedirectedpetimagingtracercandidates AT hessmannmanuela pharmacologicalcharacterizationofmutanthuntingtinaggregatedirectedpetimagingtracercandidates AT schaertlsabine pharmacologicalcharacterizationofmutanthuntingtinaggregatedirectedpetimagingtracercandidates AT bergrosseburgkarola pharmacologicalcharacterizationofmutanthuntingtinaggregatedirectedpetimagingtracercandidates AT brownchristopherj pharmacologicalcharacterizationofmutanthuntingtinaggregatedirectedpetimagingtracercandidates AT bursowgalina pharmacologicalcharacterizationofmutanthuntingtinaggregatedirectedpetimagingtracercandidates AT chikianass pharmacologicalcharacterizationofmutanthuntingtinaggregatedirectedpetimagingtracercandidates AT ebnethandreas pharmacologicalcharacterizationofmutanthuntingtinaggregatedirectedpetimagingtracercandidates AT gehrmannmiriam pharmacologicalcharacterizationofmutanthuntingtinaggregatedirectedpetimagingtracercandidates AT hoeschennicole pharmacologicalcharacterizationofmutanthuntingtinaggregatedirectedpetimagingtracercandidates AT hotzemadlen pharmacologicalcharacterizationofmutanthuntingtinaggregatedirectedpetimagingtracercandidates AT jahnstefanie pharmacologicalcharacterizationofmutanthuntingtinaggregatedirectedpetimagingtracercandidates AT johnsonpeterd pharmacologicalcharacterizationofmutanthuntingtinaggregatedirectedpetimagingtracercandidates AT khetarpalvinod pharmacologicalcharacterizationofmutanthuntingtinaggregatedirectedpetimagingtracercandidates AT kiselyovalex pharmacologicalcharacterizationofmutanthuntingtinaggregatedirectedpetimagingtracercandidates AT kottigkarsten pharmacologicalcharacterizationofmutanthuntingtinaggregatedirectedpetimagingtracercandidates AT ladewigstefanie pharmacologicalcharacterizationofmutanthuntingtinaggregatedirectedpetimagingtracercandidates AT lashuelhilal pharmacologicalcharacterizationofmutanthuntingtinaggregatedirectedpetimagingtracercandidates AT letschertsven pharmacologicalcharacterizationofmutanthuntingtinaggregatedirectedpetimagingtracercandidates AT millsmatthewr pharmacologicalcharacterizationofmutanthuntingtinaggregatedirectedpetimagingtracercandidates AT petersenkathrin pharmacologicalcharacterizationofmutanthuntingtinaggregatedirectedpetimagingtracercandidates AT primemichaele pharmacologicalcharacterizationofmutanthuntingtinaggregatedirectedpetimagingtracercandidates AT scheichchristoph pharmacologicalcharacterizationofmutanthuntingtinaggregatedirectedpetimagingtracercandidates AT schmiedelgerhard pharmacologicalcharacterizationofmutanthuntingtinaggregatedirectedpetimagingtracercandidates AT wityakjohn pharmacologicalcharacterizationofmutanthuntingtinaggregatedirectedpetimagingtracercandidates AT liulongbin pharmacologicalcharacterizationofmutanthuntingtinaggregatedirectedpetimagingtracercandidates AT dominguezcelia pharmacologicalcharacterizationofmutanthuntingtinaggregatedirectedpetimagingtracercandidates AT munozsanjuanignacio pharmacologicalcharacterizationofmutanthuntingtinaggregatedirectedpetimagingtracercandidates AT bardjonathana pharmacologicalcharacterizationofmutanthuntingtinaggregatedirectedpetimagingtracercandidates |